Evidence map›Paper›PMID 37639465›Full record

ArticlePLoS genetics2023

MYC disrupts transcriptional and metabolic circadian oscillations in cancer and promotes enhanced biosynthesis.

Juliana Cazarin, Rachel E DeRollo, Siti Noor Ain Binti Ahmad Shahidan, Jamison B Burchett, Daniel Mwangi, Saikumari Krishnaiah, Annie L Hsieh, Zandra E Walton, Rebekah Brooks, Stephano S Mello and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Circadian clock and cancer.Military Medical Research · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Juliana CazarinDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.ORCID 0000-0002-5728-1857
Rachel E DeRolloDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.
Siti Noor Ain Binti Ahmad ShahidanDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.
Jamison B BurchettDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.ORCID 0000-0003-4612-1310
Daniel MwangiDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.
Saikumari KrishnaiahDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Annie L HsiehThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-2048-7333
Zandra E WaltonThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-0465-0153
Rebekah BrooksThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Stephano S MelloDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.ORCID 0000-0002-2484-086X
Aalim M WeljieDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Chi V DangLudwig Institute for Cancer Research, New York, New York, United States of America.
Brian J AltmanDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.ORCID 0000-0002-3954-4916
University of Rochester · USThe Wistar Institute · USTranslational Therapeutics (United States) · USUniversity of Rochester Medical Center · USJohns Hopkins University · US

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Training Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3M
IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1M
C-MYC TARGETS IN THE PATHOGENESIS OF HUMAN CANCERSR01CA057341 · NCI · WISTAR INSTITUTE · PI DANG, CHI V. · 1992 to 2021
$8.3M
MYC--TRANSCRIPTION AND INTERACTION WITH P107R01CA051497 · NCI · WISTAR INSTITUTE · PI DANG, CHI V. · 1995 to 2025
$5.3M
Balance of sleep and circadian metabolic switches in DrosophilaR01DK120757 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SEHGAL, AMITA, WELJIE, AALIM M · 2019 to 2022
$2.1M
Oncogenic Disruption of the Circadian Metabolic Cycle in CancerR00CA204593 · NCI · UNIVERSITY OF ROCHESTER · PI ALTMAN, BRIAN JAMES · 2018 to 2020
$747k
Determining and enhancing metabolite fitness for metabolomics measurementsR21CA213234 · NCI · UNIVERSITY OF PENNSYLVANIA · PI WELJIE, AALIM M · 2017 to 2019
$626k
A long noncoding RNA antagonizes the PBAF complex to promote ccRCC progressionF31CA232551 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BROOKS, REBEKAH · 2019 to 2021
$111k
Disruption of circadian rhythm in hypoxiaF30CA200347 · NCI · UNIVERSITY OF PENNSYLVANIA · PI WALTON, ZANDRA ELENE · 2015 to 2016
$78k
NCI NIH HHS F30 CA200347NCI NIH HHS F31 CA232551NCI NIH HHS K12 CA090354NCI NIH HHS R00 CA204593NCI NIH HHS R01 CA051497NCI NIH HHS R01 CA057341NCI NIH HHS R21 CA213234NCI NIH HHS T32 CA009140NCI NIH HHS UG1 CA189961NIDDK NIH HHS R01 DK120757
6 · The paper itself

Abstract

The molecular circadian clock, which controls rhythmic 24-hour oscillation of genes, proteins, and metabolites in healthy tissues, is disrupted across many human cancers. Deregulated expression of the MYC oncoprotein has been shown to alter expression of molecular clock genes, leading to a disruption of molecular clock oscillation across cancer types. It remains unclear what benefit cancer cells gain from suppressing clock oscillation, and how this loss of molecular clock oscillation impacts global gene expression and metabolism in cancer. We hypothesized that MYC or its paralog N-MYC (collectively termed MYC herein) suppress oscillation of gene expression and metabolism to upregulate pathways involved in biosynthesis in a static, non-oscillatory fashion. To test this, cells from distinct cancer types with inducible MYC were examined, using time-series RNA-sequencing and metabolomics, to determine the extent to which MYC activation disrupts global oscillation of genes, gene expression pathways, and metabolites. We focused our analyses on genes, pathways, and metabolites that changed in common across multiple cancer cell line models. We report here that MYC disrupted over 85% of oscillating genes, while instead promoting enhanced ribosomal and mitochondrial biogenesis and suppressed cell attachment pathways. Notably, when MYC is activated, biosynthetic programs that were formerly circadian flipped to being upregulated in an oscillation-free manner. Further, activation of MYC ablates the oscillation of nutrient transporter proteins while greatly upregulating transporter expression, cell surface localization, and intracellular amino acid pools. Finally, we report that MYC disrupts metabolite oscillations and the temporal segregation of amino acid metabolism from nucleotide metabolism. Our results demonstrate that MYC disruption of the molecular circadian clock releases metabolic and biosynthetic processes from circadian control, which may provide a distinct advantage to cancer cells.

Indexed as

Circadian RhythmNeoplasmsProto-Oncogene Proteins c-mycAmino AcidsCell LineCell MembraneHumansMetabolomicsAmino AcidsMYC protein, humanProto-Oncogene Proteins c-myc

Identifiers

PMID37639465
PMCPMC10491404
OpenAlexW4386212835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.